NK cell

DRUG2 trials

Sponsors

Nanfang Hospital, Southern Medical University, Peking University First Hospital

Conditions

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) RelapseHepatocellular CarcinomaNK Cell

Phase 1

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

RecruitingNCT06641648

Peking University First HospitalAcute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse, NK Cell

Start: 2025-11-01End: 2027-06-30Target: 12Updated: 2026-08-05

Phase 2

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Nanfang Hospital, Southern Medical UniversityHepatocellular Carcinoma

Start: 2021-01-01End: 2023-12-31Target: 35Updated: 2021-12-28